
Release date: 2026-01-21 17:26:21 Article From: Lucius Laos Recommended: 116
This medicine may cause fluid retention and heart failure. If you experience rapid weight gain, chest pain or tightness, extreme fatigue, difficulty breathing, or swelling of the hands, feet, wrists, or ankles, seek medical attention promptly. These symptoms may indicate underlying heart problems or excessive fluid retention in the body.
Regular follow-up visits with your doctor to monitor disease progression are crucial for ensuring the efficacy of this medicine. Blood tests may be required to screen for adverse drug reactions.
Use of this medicine during pregnancy may cause harm to the fetus. If you are a woman of childbearing age, your doctor may perform a pregnancy test before initiating treatment, and medication can only be administered upon confirmation of non-pregnancy. Effective contraceptive measures must be adopted during treatment and within 3 weeks after the last dose to prevent pregnancy. If you suspect you are pregnant while taking this medicine, inform your doctor immediately.
This medicine may induce coagulation dysfunction. If you develop symptoms such as chest pain, unilateral numbness or weakness of limbs, difficulty breathing, speech impairment, or leg pain and swelling, seek medical attention immediately.
If you experience symptoms including abdominal pain, clay-colored stools, darkening of urine, loss of appetite, or yellowing of the eyes and skin, seek medical attention immediately. These symptoms may signal serious liver problems.
Ponatinib may interact with other medications, which could increase the risk of side effects or reduce the drug’s efficacy. It is imperative to inform healthcare providers of all medications you are currently taking, including prescription drugs, over-the-counter medicines, dietary supplements, and herbal products. Common drugs that may interact with ponatinib are listed below:
Ketoconazole: This antifungal medication can increase the blood concentration of ponatinib, thereby raising the risk of side effects.
Rifampicin: This antibiotic may decrease the blood concentration of ponatinib, which could potentially reduce its therapeutic effect.
St. John’s Wort: This herbal supplement can accelerate the metabolic breakdown of ponatinib in the body, lowering its treatment efficacy.
Warfarin: Concurrent use of ponatinib with anticoagulants such as warfarin may increase the risk of bleeding.
Atorvastatin: Co-administration of ponatinib with cholesterol-lowering drugs like atorvastatin may increase the risk of muscle injury.
The use of ponatinib during pregnancy is not recommended, as the drug may cause fetal harm and poses potential risks of fetal malformation or miscarriage. If you are pregnant or planning to become pregnant, you should promptly consult your healthcare provider to discuss alternative treatment options. Women of childbearing age must use reliable contraceptive methods while taking ponatinib and for a specific period after stopping the medication. If you become pregnant accidentally while taking ponatinib, contact your healthcare provider immediately to jointly discuss a management plan to safeguard maternal health during pregnancy.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3512025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5522024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3522025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3272025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3932025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3262025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3012025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643